Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO) recently featured on The BioMedWire Podcast, where CEO and Co-Founder Dr. Meesha Dogan outlined the company’s growth strategy and expansion into India. The company focuses on improving cardiovascular disease prevention and early detection through precision medicine powered by epigenetics, genetics, and artificial intelligence. During the podcast, Dr. Dogan highlighted the significance of Cardio Diagnostics’ progress through the Medicare reimbursement process, noting that CPT coding and payment steps have been completed, while coverage determination remains underway.
The company’s expansion into India is a key component of its growth strategy, facilitated through partnerships with Aimil Ltd. and Dr. Lal PathLabs. These collaborations aim to make Cardio Diagnostics’ innovative tests accessible in one of the world’s most populous nations, where cardiovascular disease is a leading cause of mortality. The partnerships leverage local expertise to distribute and implement the company’s AI-driven integrated genetic-epigenetic engine, which is designed to personalize cardiovascular care. This move is expected to significantly expand the company’s market reach and impact patient outcomes globally.
Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that aims to make cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The company was formed to further develop and commercialize clinical tests by leveraging a proprietary AI-driven Integrated Genetic-Epigenetic Engine (Core Technology). This technology positions the company to become a leading medical technology firm in improving prevention, detection, and treatment of cardiovascular disease.
The Medicare reimbursement progress is a critical milestone for Cardio Diagnostics, as it could pave the way for broader adoption of its tests among healthcare providers and patients. With CPT coding and payment steps completed, the company is now awaiting coverage determination, which will dictate the extent to which Medicare beneficiaries can access these tests. Successful coverage would likely enhance the company’s revenue potential and credibility within the healthcare industry.
For more details, the full press release is available at https://ibn.fm/0VjIz. The latest news and updates relating to CDIO can be found in the company’s newsroom at https://ibn.fm/CDIO.
